OTTAWA, April 24 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) announced today successful in vitro or “bench” testing of a new compound designed to be a selective inhibitor of Protein Kinase C Theta (“PKC theta”) showing indication of selectivity to and inhibition of PKC theta. This new compound follows on the successful completion of the research and development phase of preclinical testing for the Company’s selective inhibitor of PKC alpha, PhG-alpha-1, announced last week.
